Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Eli Lilly and Company

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions
Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly's connected insulin solutions, currently in... 
Tickers LLY
From PR Newswire
Lilly to Participate in Cowen Health Care Conference
Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41st Annual Health Care Conference on Thursday, March 4, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific... 
Tickers LLY
From PR Newswire
Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
In the 52-week SURPASS-3 study - the longest in the program to date - the highest dose of tirzepatide reduced A1C by 2.37 percent and body weight by 12.9 kg (28.4 lb., 13.9 percent) 
Tickers LLY
From PR Newswire
Kimberly H. Johnson Elected to Lilly Board of Directors
The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Kimberly H. Johnson as a new member, effective February 16, 2021. As a member of Lilly's board, she will serve on both the... 
Tickers LLY
From PR Newswire
Lilly To Participate in SVB Leerink Global Healthcare Conference
Eli Lilly and Company (NYSE:LLY) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Ilya Yuffa, Lilly senior vice president and president of... 
Tickers LLY
From PR Newswire
Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19
- Bamlanivimab and etesevimab administered together authorized for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19 
Tickers LLY
From PR Newswire
Lilly Appoints Anat Ashkenazi Chief Financial Officer
Eli Lilly and Company (NYSE: LLY) today announced the appointment of Anat Ashkenazi as senior vice president and chief financial officer. Ms. Ashkenazi, who most recently served in the role of senior... 
Tickers LLY
From PR Newswire
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference
Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, March 15, 2021 to provide an update on its Alzheimer's disease program and discuss results from the Phase 2 TRAILBLAZER-ALZ study for... 
Tickers LLY
From PR Newswire
Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021. Anne White, senior vice president and president, Lilly Oncology,... 
Tickers LLY
From PR Newswire
Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients
Eli Lilly and Company (NYSE: LLY) has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that are intended to provide... 
Tickers LLY
From PR Newswire
Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results
- Revenue in the fourth quarter of 2020 increased 22 percent, driven by volume growth of 24 percent. Excluding bamlanivimab revenue of $871 million, fourth-quarter 2020 revenue grew 7 percent. 
Tickers LLY
From PR Newswire
Lilly, Life for a Child and Beyond Type 1 advance partnership to improve diabetes care in resource-limited countries
Partnership expands access to care for children and young people with diabetes to approximately 150,000 in 65 countries 
Tickers LLY
From PR Newswire
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an... 
Tickers LLY
From PR Newswire
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in... 
Tickers GSK LLY VIR
From PR Newswire
New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent
- BLAZE-1 trial met primary endpoint and key secondary endpoints with high statistical significance 
Tickers LLY
From PR Newswire
Lilly Completes Acquisition of Prevail Therapeutics
Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery... 
Tickers LLY PRVL
From PR Newswire
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The... 
Tickers LLY
From PR Newswire
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies,... 
Tickers LLY MRUS
From PR Newswire
Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021. Lilly will also conduct a conference call on that day with the... 
Tickers LLY
From PR Newswire
Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund
Fund will provide support for minority-owned early-stage healthcare companies and is a component of Lilly's racial justice efforts 
Tickers LLY
From PR Newswire
Gabrielle Sulzberger Elected to Lilly Board of Directors
The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Gabrielle Sulzberger as a new member, effective January 25, 2021. As a member of Lilly's board, she will serve on both the Audit... 
Tickers LLY
From PR Newswire
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) which is being investigated as a potential new treatment to reduce the... 
Tickers LLY
From PR Newswire
Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial
Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients... 
Tickers LLY
From PR Newswire
Lilly to Participate in J.P. Morgan Healthcare Conference
Eli Lilly and Company (NYSE:LLY) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. David A. Ricks, Lilly's chairman and chief executive officer, will... 
Tickers LLY
From PR Newswire
Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico
Study will provide real-world data and insight on various infusion setting experiences 
Tickers LLY
From PR Newswire
Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance
- Lilly expects to deliver strong financial and operational performance in 2021, highlighted by volume-based revenue growth, operating margin expansion, pipeline advancements and solid cash flow. 
Tickers LLY
From PR Newswire
Lilly Announces Agreement to Acquire Prevail Therapeutics
Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address... 
Tickers LLY PRVL
From PR Newswire
Lilly Announces 15 Percent Dividend Increase
The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter of 2021 will be $0.85 per share on... 
Tickers LLY
From PR Newswire
Lilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study
- New IDEAS study will focus on African American and Latino participants 
Tickers LLY
From PR Newswire
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial... 
Tickers INCY LLY
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.